DE60336546D1 - Testagentien zur beurteilung der pharmakologischen wirkung eines arzneistoffs sowie verfahren und reagentien zum screening eines arzneistoffs mit ausgezeichneter verabreichungswirkung und/oder geringer nebenwirkung aus enzyme, enzyminhibitoren oder rezeptorliganden umfassenden arzneistoffen und/oder prodrugs davon - Google Patents

Testagentien zur beurteilung der pharmakologischen wirkung eines arzneistoffs sowie verfahren und reagentien zum screening eines arzneistoffs mit ausgezeichneter verabreichungswirkung und/oder geringer nebenwirkung aus enzyme, enzyminhibitoren oder rezeptorliganden umfassenden arzneistoffen und/oder prodrugs davon

Info

Publication number
DE60336546D1
DE60336546D1 DE60336546T DE60336546T DE60336546D1 DE 60336546 D1 DE60336546 D1 DE 60336546D1 DE 60336546 T DE60336546 T DE 60336546T DE 60336546 T DE60336546 T DE 60336546T DE 60336546 D1 DE60336546 D1 DE 60336546D1
Authority
DE
Germany
Prior art keywords
enzyme
medicament
pharmaceutical agent
medicine
effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60336546T
Other languages
English (en)
Inventor
Asuka Ito
Tadashi Kohno
Isaburo Hosoi
Junko Hirayama
Kenji Maeda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tokyo Gas Co Ltd
Original Assignee
Tokyo Gas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokyo Gas Co Ltd filed Critical Tokyo Gas Co Ltd
Application granted granted Critical
Publication of DE60336546D1 publication Critical patent/DE60336546D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1206—Administration of radioactive gases, aerosols or breath tests
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/40—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving amylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Atmospheric Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE60336546T 2002-02-21 2003-02-20 Testagentien zur beurteilung der pharmakologischen wirkung eines arzneistoffs sowie verfahren und reagentien zum screening eines arzneistoffs mit ausgezeichneter verabreichungswirkung und/oder geringer nebenwirkung aus enzyme, enzyminhibitoren oder rezeptorliganden umfassenden arzneistoffen und/oder prodrugs davon Expired - Lifetime DE60336546D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002044526 2002-02-21
JP2002044791 2002-02-21
PCT/JP2003/001868 WO2003071271A1 (fr) 2002-02-21 2003-02-20 Agents de tests pour evaluer l'effet pharmacologique de medicaments, et procede et reactifs pour selectionner des medicaments ayant un excellent effet d'administration et/ou peu d'effets secondaires parmi des medicaments avec enzymes, inhibiteurs d'enzymes ou ligands de recepteurs et/ou promedicaments de ceux-ci

Publications (1)

Publication Number Publication Date
DE60336546D1 true DE60336546D1 (de) 2011-05-12

Family

ID=27759664

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60336546T Expired - Lifetime DE60336546D1 (de) 2002-02-21 2003-02-20 Testagentien zur beurteilung der pharmakologischen wirkung eines arzneistoffs sowie verfahren und reagentien zum screening eines arzneistoffs mit ausgezeichneter verabreichungswirkung und/oder geringer nebenwirkung aus enzyme, enzyminhibitoren oder rezeptorliganden umfassenden arzneistoffen und/oder prodrugs davon

Country Status (12)

Country Link
US (1) US7404945B2 (de)
EP (1) EP1486785B1 (de)
JP (1) JPWO2003071271A1 (de)
AT (1) ATE503998T1 (de)
AU (1) AU2003211602B2 (de)
CA (1) CA2474993A1 (de)
DE (1) DE60336546D1 (de)
MX (1) MXPA04008180A (de)
NO (1) NO20043756L (de)
NZ (1) NZ534462A (de)
PT (1) PT1486785E (de)
WO (1) WO2003071271A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3640342A1 (de) 2004-05-13 2020-04-22 Nanobiosym, Inc. Nano-pcr: verfahren und vorrichtung zur amplifikation und detektion von nukleinsäuren
ES2450690T3 (es) 2005-06-30 2014-03-25 Otsuka America Pharmaceutical, Inc. Método para individualizar la terapia con levodopa/carbidopa utilizando una prueba respiratoria
JP2009534033A (ja) 2006-04-21 2009-09-24 ナノバイオシン，インコーポレイテッド 薬物発見のための単一分子プラットホーム：抗癌剤および抗ウイルス剤の発見を含む薬物発見のための方法および装置
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
US10933417B2 (en) 2013-03-15 2021-03-02 Nanobiosym, Inc. Systems and methods for mobile device analysis of nucleic acids and proteins
EP3083933A1 (de) 2013-12-20 2016-10-26 Biogen MA Inc. Verwendung von perfusionssaatkulturen zur verbesserung der biopharmazeutischen fed-batch-produktionskapazitäten und der produktqualität
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625125A (en) 1994-08-09 1997-04-29 Dnx Biotherapeutics Phospholipase A2 expressing transgenic animals
JPH1180034A (ja) * 1997-09-12 1999-03-23 Tokyo Gas Co Ltd フェニルアラニン水酸化酵素活性検査剤
JP3340699B2 (ja) * 1998-06-05 2002-11-05 東京瓦斯株式会社 膵外分泌機能診断剤
US6284219B1 (en) * 1998-06-30 2001-09-04 Phenome Sciences Inc. In vivo determination of metabolic function for use in therapy management
GB9826899D0 (en) 1998-12-08 1999-01-27 Knoll Ag Methods to treat depression and other psychiatric disorders and assays for compounds
WO2000053800A1 (en) 1999-03-09 2000-09-14 Flohe Leopold METHOD TO SEARCH FOR MALE ANTIFERTILITY DRUGS BASED ON PHGPx ACTIVITY DETERMINATION
AU2001261394A1 (en) * 2000-05-18 2001-11-26 Metabolic Solutions, Inc. Reverse isotope dilution assay and lactose intolerance assay

Also Published As

Publication number Publication date
MXPA04008180A (es) 2005-05-16
AU2003211602A1 (en) 2003-09-09
NO20043756L (no) 2004-09-08
US7404945B2 (en) 2008-07-29
PT1486785E (pt) 2011-05-12
EP1486785A4 (de) 2008-03-05
US20050079564A1 (en) 2005-04-14
JPWO2003071271A1 (ja) 2005-06-16
EP1486785B1 (de) 2011-03-30
AU2003211602B2 (en) 2008-05-22
EP1486785A1 (de) 2004-12-15
NZ534462A (en) 2007-06-29
ATE503998T1 (de) 2011-04-15
CA2474993A1 (en) 2003-08-28
WO2003071271A1 (fr) 2003-08-28

Similar Documents

Publication Publication Date Title
ATE414519T1 (de) Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit
DE602005007339D1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
AR055669A1 (es) Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
KR20230042756A (ko) 고형 종양의 치료에 사용하기 위한 lsd1 억제제의 조합물
BRPI0515885A (pt) derivados de ftalazinona, sua preparação e uso como agentes farmacêuticos
ATE473976T1 (de) Dipeptidylpeptidase-iv-inhibierende verbindungen, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese als wirkstoffe enthalten
ECSP088246A (es) Nuevos derivados de benzotiazolona
BRPI0519443A2 (pt) composto orgÂnicos
DE60336546D1 (de) Testagentien zur beurteilung der pharmakologischen wirkung eines arzneistoffs sowie verfahren und reagentien zum screening eines arzneistoffs mit ausgezeichneter verabreichungswirkung und/oder geringer nebenwirkung aus enzyme, enzyminhibitoren oder rezeptorliganden umfassenden arzneistoffen und/oder prodrugs davon
SI2903616T1 (en) The use of masitinib in combination with gemcitabine for the treatment of a subgroup of patients suffering from foot-and-mouth disease
BRPI0409427A (pt) composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo
ATE540679T1 (de) Verfahren zur verringerung der gastrointestinalen toxizität durch verabreichung von tegafur
Peh et al. The combination of vemurafenib and procaspase-3 activation is synergistic in mutant BRAF melanomas
ES2318113T3 (es) Combinaciones farmaceuticas de meloxicam,fosfato de codeina y paracetamol.
DE69506197D1 (de) Verwendung eines Ascorbyl-tocopherylphosphats zur Herstellung eines Arzneimittels zur Behandlung der Pankreatitis
CN1530102B (zh) 含有α-硫辛酸、氨溴索和/或血管紧张素转化酶(ACE)抑制剂的药物制剂及其治疗神经变性疾病的用途
DE602005003907D1 (de) Benzothiadiazinderivate, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die diese enthalten
ATE538789T1 (de) Pharmazeutische zusammensetzung mit einem phenylamidin-derivat und verfahren zur verwendung der pharmazeutischen zusammensetzung in kombination mit einem antimykotischen mittel
ATE370927T1 (de) Pentensäurederivate, verfahren zu deren herstellung, pharmazeutische zusammensetzungen, die diese enthalten, und deren therapeutische anwendung
BRPI0416745A (pt) novos compostos
BR9813554A (pt) Composto, uso do mesmo, processo para produzi-lo, composição farmacêutica ou veterinária, e, inibidor de metaloproteinase
UA96282C2 (ru) 3,5-замещенные пиперидины как ингибиторы ренина
BRPI0409951A (pt) derivados de anilina, sua produção e uso como agentes farmacêuticos
CN105476981B (zh) 漆树酸作为棘球蚴甘油醛三磷酸脱氢酶的抑制剂和作为治疗包虫病药物的应用
TH33140A (th) วิธีการเตรียมสารยับยั้ง hiv-โปรทีเอส และสารมัธยันตร์ สำหรับการเตรียมสารยับยั้ง hiv-โปรทีเอส